secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2025-11-17T23:59:59+00:00
Accession:  0001759425-25-000057
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum receives Sandoz Paragraph IV notice challenging Livmarli patents; plans to sue
--------------------------------------------------------------------------------

- Sandoz filed ANDA seeking FDA approval for generic Livmarli (maralixibat).
- Sandoz alleges five Livmarli Orange Book patents are invalid or not infringed.
- Mirum has 45 days to sue, triggering a 30-month FDA approval stay.
- Mirum expects additional Paragraph IV notices from other ANDA filers.
- Company vows to vigorously enforce IP and seek a permanent injunction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942525000057/0001759425-25-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942525000057/mirm-20251117.htm
  HTML page:      https://secwatch.observer/filing/0001759425-25-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer